🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Max Healthcare Institute Limited MAXHEALTH NSEAIPHARMA

Healthcare · Medical Care Facilities · India
https://www.maxhealthcare.in
Company Profile ↓
₹1,099.00
-12.04% 1Y
Mkt Cap₹1.07 L Cr
P/E99.82
P/B10.01
Div. Yield0.18%
52W High₹1,278.23
52W Low₹929.95
Book Value₹110.43
EPS (TTM)₹11.01

Company Overview

Max Healthcare Institute Limited provides medical and healthcare services in India. It offers services in various specialties, including cardiac sciences, orthopedics, oncology, renal sciences, neurosciences, minimal access and general surgery, pulmonology, obstetrics, gynecology, pediatrics, and nephrology, liver and biliary sciences, gastroenterology and Gi surgery, Internal Medicine, plastic and reconstructive surgery, and organ transplants, as well as ear, nose, and throat. The company also provides Max@Home, a platform that offers health and wellness services at home; and MaxLab, which provides diagnostic testing services to patients. In addition, it provides organ and tissue donation, preventive health checks, ambulance services, immigration services, air ambulance, and insurance and TPA services. The company operates through a network of healthcare facilities, including hospitals and medical centres. The company was incorporated in 2001 and is based in Gurugram, India.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 22.4% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 17.5%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.32.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹8,225.43 Cr (+19.0% YoY); net profit ₹1,442.41 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +19.0%, earnings +34.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 22.4%, profit CAGR 9.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:22.37%
1 Year:19.03%

Compounded Profit Growth

5 Years:9.34%
1 Year:34.07%

Stock Price Performance

1 Year:-12.04%
6 Months:+8.61%
3 Months:+9.26%
1 Month:+7.50%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

AI Exposure AI Healthcare / AI in Hospital Operations
Core Focus

Max Healthcare uses AI in radiology, ICU early-warning, and hospital workflow optimisation across its 17+ hospital network.

Key Initiatives
  • Clinical AI & diagnostics Max Healthcare adopts AI-assisted imaging, diagnostics and clinical-decision tools to scale specialist care across its hospital network.
  • AI in hospital operations Predictive analytics for bed management, demand and throughput improve asset utilisation in a capacity-constrained system.
  • Digital patient experience AI-enabled triage, appointment and care-pathway tools improve patient access and engagement.
Why Investors Should Care
  • AI supports both clinical quality and asset utilisation in a fast-growing hospital chain.
  • Strong growth (~27% five-year revenue CAGR) and healthy margins.
  • Defensive healthcare demand with capacity-led expansion runway.
  • Premium P/E ~66 reflects growth and scarcity of quality hospital assets.
AI InvestmentCapex includes AI-led equipment upgrade; partnerships with health-AI startups.
AI RevenueRevenue ~₹6,500 Cr; ARPU growing on premium services.
ROI (Now)EBITDA margin ~26%; ROE ~16%.
ROI (Expected)Capacity expansion + AI clinical decision support to drive 18-20% growth.

Curated from public filings and analyst commentary; figures are illustrative.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 22.4% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading at a high P/E of 99.8.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
99.82
Industry PE
39.97
Forward P/E
45.22
PEG Ratio
-
Book Value
₹110.43
Price to Book
10.01
P/S
12.86
EV/EBITDA
50.70
Dividend Yield
0.18%

Growth (CAGR)

Revenue 5Y
22.37%
Profit 5Y
9.34%
Revenue (YoY)
19.03%
Earnings (YoY)
34.07%

Profitability & Returns

ROCE
12.57%
ROE
13.42%
ROA
8.37%
Profit Margin
17.54%
Op Margin
22.82%
Gross Margin
78.24%
EPS (Latest Qtr)
₹3.50
EPS (TTM)
₹11.01

Balance Sheet & Liquidity

Debt/Equity
0.32
Quick Ratio
0.84
Current Ratio
0.89
Debt
₹3,478.36 Cr
Total Assets
₹17,230.94 Cr
Current Assets
₹1,944.79 Cr
Working Capital
₹-242.15 Cr

Ownership

Promoter Holding
27.14%
Chg in Prom Hold
3.43%
FII / Inst Holding
59.06%
Chg in FII Hold
-0.14%

Financial Snapshot

Enterprise Value
₹1.07 L Cr
Total Revenue (TTM)
₹8,225.43 Cr
EBITDA
₹2,337.15 Cr
Free Cash Flow
₹148.79 Cr
Operating Cash Flow
₹1,633.32 Cr
Shares Outstanding
₹97.31 Cr
Gross Margin
78.24%
Payout Ratio
10.16%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,562.00 55.36 ₹1.06 L Cr 0.08% 13.75% 11.74% 17.73% 14.28%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 1,215.00 Cr1,285.00 Cr1,363.00 Cr1,335.00 Cr1,423.00 Cr1,543.00 Cr1,707.00 Cr-1,909.74 Cr2,027.57 Cr2,135.47 Cr2,067.52 Cr2,142.89 Cr
Cost of Revenue --------409.43 Cr445.24 Cr464.89 Cr440.35 Cr439.54 Cr
Gross Profit --------1,500.31 Cr1,582.33 Cr1,670.58 Cr1,627.17 Cr1,703.35 Cr
Operating Expenses 874.00 Cr948.00 Cr976.00 Cr949.00 Cr1,041.00 Cr1,156.00 Cr1,257.00 Cr-1,089.52 Cr1,163.56 Cr1,203.53 Cr1,200.10 Cr1,219.94 Cr
Operating Income 280.00 Cr281.00 Cr329.00 Cr325.00 Cr312.00 Cr310.00 Cr367.00 Cr-410.79 Cr418.77 Cr467.05 Cr427.07 Cr483.41 Cr
EBITDA 340.00 Cr337.00 Cr387.00 Cr386.00 Cr382.00 Cr387.00 Cr451.00 Cr-558.54 Cr559.42 Cr608.05 Cr535.48 Cr654.26 Cr
Interest Expense 20.00 Cr19.00 Cr9.00 Cr11.00 Cr21.00 Cr24.00 Cr34.00 Cr-55.21 Cr54.85 Cr53.92 Cr59.67 Cr66.66 Cr
Pretax Income 301.00 Cr303.00 Cr366.00 Cr360.00 Cr336.00 Cr321.00 Cr374.00 Cr-402.50 Cr400.43 Cr446.03 Cr364.54 Cr464.58 Cr
Tax Provision 51.17 Cr63.63 Cr87.84 Cr72.00 Cr84.00 Cr83.46 Cr93.50 Cr-83.50 Cr92.46 Cr-45.27 Cr63.62 Cr122.36 Cr
Net Income 251.00 Cr240.00 Cr277.00 Cr289.00 Cr252.00 Cr236.00 Cr282.00 Cr-319.00 Cr307.97 Cr491.30 Cr300.92 Cr342.22 Cr
Diluted EPS 2.582.472.852.982.592.432.90-3.263.155.023.093.50

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 1,608.00 Cr1,729.00 Cr1,691.00 Cr1,059.00 Cr2,508.00 Cr-4,488.95 Cr5,309.48 Cr6,910.36 Cr8,225.43 Cr
Cost of Revenue ------921.10 Cr1,117.95 Cr1,476.89 Cr1,789.91 Cr
Gross Profit ------3,567.85 Cr4,191.53 Cr5,433.47 Cr6,435.52 Cr
Operating Expenses 1,467.00 Cr1,616.00 Cr1,535.00 Cr965.00 Cr2,101.00 Cr-2,522.61 Cr2,906.96 Cr3,857.22 Cr4,558.18 Cr
Operating Income 45.00 Cr19.00 Cr53.00 Cr48.00 Cr233.00 Cr-1,045.24 Cr1,284.57 Cr1,576.25 Cr1,877.34 Cr
EBITDA 141.00 Cr113.00 Cr156.00 Cr94.00 Cr407.00 Cr-1,367.23 Cr1,654.86 Cr1,914.54 Cr2,337.15 Cr
Interest Expense 100.00 Cr99.00 Cr101.00 Cr83.00 Cr179.00 Cr-71.32 Cr44.56 Cr148.75 Cr215.04 Cr
Pretax Income 5.00 Cr-15.00 Cr8.00 Cr13.00 Cr-69.00 Cr-1,063.72 Cr1,365.32 Cr1,406.37 Cr1,675.58 Cr
Tax Provision -11.80 Cr-9.75 Cr8.16 Cr-13.00 L-46.23 Cr--39.79 Cr307.68 Cr330.49 Cr233.17 Cr
Net Income 16.00 Cr-25.00 Cr-059.00 Cr-138.00 Cr-1,103.51 Cr1,057.64 Cr1,075.88 Cr1,442.41 Cr
Diluted EPS 0.29-0.47-0.061.10-1.426.2411.3610.8411.01-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 3,146.00 Cr3,302.00 Cr3,355.00 Cr3,974.00 Cr8,543.00 Cr-10,101.85 Cr11,999.94 Cr15,214.48 Cr17,230.94 Cr
Current Assets ------1,943.07 Cr1,706.18 Cr1,592.57 Cr1,944.79 Cr
Cash & Equivalents ------1,374.33 Cr979.84 Cr661.58 Cr665.80 Cr
Inventory ------76.23 Cr79.84 Cr106.21 Cr114.28 Cr
Receivables ------336.12 Cr462.69 Cr687.31 Cr969.75 Cr
Total Liabilities ------2,692.26 Cr3,591.80 Cr5,833.61 Cr6,484.31 Cr
Current Liabilities ------1,045.57 Cr1,248.71 Cr1,806.17 Cr2,186.94 Cr
Long Term Debt ------496.58 Cr1,056.44 Cr2,270.06 Cr2,438.66 Cr
Total Debt 874.00 Cr981.00 Cr1,003.00 Cr875.00 Cr1,101.00 Cr-908.25 Cr1,294.56 Cr3,010.29 Cr3,478.36 Cr
Total Equity 1,192.00 Cr1,164.00 Cr963.00 Cr2,553.00 Cr5,639.00 Cr-7,409.59 Cr8,408.14 Cr9,380.87 Cr10,746.63 Cr
Shares Outstanding ------97.09 Cr97.19 Cr97.21 Cr97.31 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 156.00 Cr166.00 Cr89.00 Cr77.00 Cr118.00 Cr-1,284.13 Cr1,121.67 Cr1,437.96 Cr1,633.32 Cr
Investing Cash Flow -104.00 Cr-124.00 Cr-17.00 Cr-2,641.00 Cr206.00 Cr--102.32 Cr-1,285.45 Cr-1,610.69 Cr-1,688.99 Cr
Financing Cash Flow -48.00 Cr-48.00 Cr-74.00 Cr2,353.00 Cr191.00 Cr--288.56 Cr-263.74 Cr-163.16 Cr59.27 Cr
Capital Expenditure -115.00 Cr-66.00 Cr-116.00 Cr-90.00 Cr-117.00 Cr--335.61 Cr-785.95 Cr-944.48 Cr-1,484.53 Cr
Free Cash Flow 41.00 Cr100.00 Cr-27.00 Cr-13.00 Cr1.00 Cr-948.52 Cr335.72 Cr493.48 Cr148.79 Cr
Net Change in Cash 4.00 Cr-6.00 Cr-2.00 Cr-210.00 Cr516.00 Cr-893.25 Cr-427.52 Cr-335.89 Cr3.60 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ------79.5%78.9%78.6%78.2%
Operating Margin % 2.8%1.1%3.1%4.5%9.3%-23.3%24.2%22.8%22.8%
Net Margin % 1.0%-1.4%-0.0%5.6%-5.5%-24.6%19.9%15.6%17.5%
ROE % 1.3%-2.1%-0.0%2.3%-2.4%-14.9%12.6%11.5%13.4%
ROCE % ------11.5%11.9%11.8%12.5%

Shareholding Pattern

Insiders
27.14%
Institutions
59.06%
Public Float
81.06%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MAXHEALTH

Google News Mon, 29 Jun 2026

Three Days Left Until Max Healthcare Institute Limited (NSE:MAXHEALTH) Trades Ex-Dividend - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxPc1VYT0p4T0V4aTRfUDhSNDVxa1FzX2RzVWlyOVp2ZlR6eHQxaDNGZVNDdjMzbDhtTUtnQUpfMlphREZPZ3M3OVptbFpHOVR0b1NoOVhqTGpzQkExR0Z2UXEwOXFWWEItSzdTTDkydFRnbll4bFA2TG9reHVMUkk5dUhHRHhSUUZHZ1JwVj…

Google News hu, 21 May 2026

Max Healthcare shares fall up to 7% as Q4 results miss estimates - TradingView

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxOMmUxeTB2MHZZWXFndHFEQ0ZfdmVqTk5lX2o3cU16YUZwVml0aHpmS0Z0UkdBbVV2eVZwWEl3VGs1OGJQYXZGSDJET2RiemE2bXJxNUw1VTUwWlBSYXhEODllT0lUTlR6aGFkOF9YX3F0Ym0tYUhZME9Gdlc1aVAtbFZxZTlUUGs1Q0hFQ2…

Google News Fri, 14 Nov 2025

Investors in Max Healthcare Institute (NSE:MAXHEALTH) have seen fantastic returns of 794% over the past five years - webull.com

<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE83bi1ITHVyMTIwZTNDRXJiYlZKMmhZLVR1YTZERmhQaWI1ZGFfLVRnU0tyQ2ZGSE8tdkdfS2VCMFNWallpUTh0TU9SUE1Wc1dEQlFRaDZINUg?oc=5" target="_blank">Investors in Max Healthcare Institute (NSE:MAXHE…

Google News hu, 18 Jun 2026

Stock Picks Today: Tata Motors PV, Shyam Metalics, Titan, Max Health, United Spirits, Thyrocare And More On Brokerages' Radar - NDTV Profit

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxPbExLbzJqcEo5OTQzS0FwV0k1ZjM3YmR3UWxqUWtoQzNPRThQUzVVSXdoN3FMeWVJbXRuQ1M1RVplQUNXbWN4RmpTZzl2ZGQtUjVvVG94ZTVDTi00WVhVN0VTTG5UZW9JOFRwZ05LWmhLLUd6dWZtWFlBN3Qtc3hsV09iSk8wTFJVVTFRZz…

Google News Sat, 23 May 2026

Analysts Just Made A Major Revision To Their Max Healthcare Institute Limited (NSE:MAXHEALTH) Revenue Forecasts - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxQSDBkT3ZjVGtmbU4yTThZZXZwUm10bDZpYy1OSFBkVkVNU2lyYkw2RkhmTnl1aWFfbWxOdHc3ZTZvcUxKa1pud0FJQjVjZ3lvQXJpQU4zdlBQdzAtVENISnFLNnBuaUt0RnR6dlJkY2k2UEd3S0dXNkUxTDZZUzJaT1AwUVhPMzlacDRXTn…

Google News Mon, 30 Mar 2026

BNP Paribas buys stakes in 4 stocks via block deals; LG Electronics, Max Health & 2 more - The Economic Times

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxOdzJ5bTIwdmZTYlFISVo5azBsOTg5VmdKQV94VDlOaFNsMVBPc1NCaGFtaFNHcTNBZVhjWVBvQXNXMFpTU0hBM0ktWjZVV3ZiVzNZNEZlZkJkcWtfWlFoMmE2X0JOajc5a1dQQld3NUtuSElhSm5zdWRPUG1pLXh1LWNqckZNSjJaNjR2UW…

MAXHEALTH — Frequently Asked Questions

What is the current share price of Max Healthcare Institute Limited (MAXHEALTH)?

As of 2026-07-15 09:52 IST, Max Healthcare Institute Limited (MAXHEALTH) trades at ₹1,099.00 on NSE. Its 52-week range is ₹929.95 to ₹1,278.23.

What is the market capitalisation of MAXHEALTH?

Max Healthcare Institute Limited (MAXHEALTH) has a market capitalisation of ₹1.07 L Cr on NSE.

What is the P/E ratio of MAXHEALTH?

MAXHEALTH trades at a trailing price-to-earnings (P/E) ratio of 99.82. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 10.01.

Does MAXHEALTH pay a dividend?

Max Healthcare Institute Limited (MAXHEALTH) currently offers a dividend yield of 0.18%.

What is the return on equity (ROE) of MAXHEALTH?

MAXHEALTH has a return on equity (ROE) of 13.42%. Its return on capital employed (ROCE) is 12.57%.

Is MAXHEALTH a good stock to buy?

This page provides a data-driven analysis of Max Healthcare Institute Limited (MAXHEALTH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space